Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis C vaccine therapy - GSK/ReiThera

Next Previous
X
Search
Drug Profile

Hepatitis C vaccine therapy - GSK/ReiThera

Alternative Names: Ad6NSmut; AdCh3NSmut; AdCh3NSmut1; Hepatitis C vaccine - Okairos AG; MVA-NSmut; PerCvax; ProCvax; TerCvax

Latest Information Update: 02 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Okairos AG; University of Oxford
  • Developer GSK; ReiThera; University of Oxford
  • Class Hepatitis C vaccines; Vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-II for Hepatitis C (Prevention) in USA (IM)
  • 02 Oct 2019 Efficacy, safety and immunogenicity data from a phase I/II trial in presented at the IDWeek 2019
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Hepatitis-C (Prevention) in Ireland (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top